ClinicalTrials.gg
RecruitingNCT06712355Updated Oct 14, 2026

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

A Phase 3 interventional study of Pumitamig and Atezolizumab in Extensive-stage Small-cell Lung Cancer, sponsored by BioNTech SE. Recruiting at 225 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by BioNTech SE · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Oct 14, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
621
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 629 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Planned enrollment
27th of 550
621 · median 55
Started
2025
with 39 others
Phase 3
50 of 629
11 open now
Primary completion
2029-04
later than 141 of 181 live
Registered
560th of 629
by date

Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 27th largest by planned enrollment of the 550 interventional ones that give a count, is one of 40 that started in 2025, is one of 50 in phase 3, reaches primary completion later than 141 of the 181 other live ones, and was the 560th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

111 of the 629 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 629 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).

Read the detailed description

There are two stages in this study: Stage 1 will have two treatment arms and one control arm, and Stage 2 will have a treatment arm and a control arm. The control arms in Stages 1 and 2 are the same.

Each stage of the study consists of a screening period (up to 21 days), an induction period followed by a maintenance period (until confirmed disease progression, intolerable toxicity, participant withdrawal, study termination or up to 2 years [whichever occurs first]), and a follow-up (FU) period for all participants (2 safety FU visits and survival FU visits).

In Stage 1, eligible participants will be randomized (1:1:1) to the arms. In Stage 2, participants will then be randomized (1:1) to the arms. The randomization will be stratified based on the following factors:

  1. Brain or liver metastases per investigator assessment (presence versus absence);
  2. Smoking status (smoker versus never-smoker); and
  3. Geography.

Participants will be allowed to switch to cisplatin if carboplatin is not tolerated at the investigator's discretion.

03

Conditions studied

  • Extensive-stage Small-cell Lung Cancer

Keywords

  • First-line ES-SCLC
  • SCLC
  • Immunotherapy in combination with chemotherapy
  • Untreated
  • Bispecific antibody
  • Programmed death-ligand 1 (PD-L1)
  • Vascular endothelial growth factor (VEGF) A
  • Immunotherapy
  • Combination with other investigational agents
  • Pumitamig
  • BNT327
  • Check point inhibitor
  • Lung cancer
  • Etoposide
  • Carboplatin
  • Cisplatin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have or cytologically confirmed ES-SCLC (using the AJCC [American Joint Committee on Cancer] tumor node staging system combined with Veterans Administration Lung Study Group [VALG]'s two stage classification scheme). For AJCC tumor node metastasis staging system: AJCC 8th edition stage IV (T any, N any, M1a/b/c), or T3\~4 for multiple lung nodules or tumor/nodule volume that cannot be encompassed in a tolerable radiotherapy plan.
  • Have not had prior systemic therapy for ES-SCLC. However, participants with prior chemoradiotherapy for limited-stage-SCLC must have been treated with curative intent and had a treatment-free interval of at least 6 months after the last chemotherapy, radiotherapy, or chemoradiotherapy before diagnosis of ES-SCLC to be eligible.
  • Have at least one as the targeted lesion based on v1.1. Lesions treated after prior local treatment (radiotherapy, ablation, interventional procedures, etc.) are generally not considered as target lesions. If the lesion with prior local treatment is the only targeted lesion, evidence-based radiology must be provided to demonstrate disease progression (the single bone metastasis or the single central nervous system metastasis should not be considered as a measurable lesion).
  • (ECOG) performance status of 0 or 1.
  • Adequate hematologic and organ function as defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Have or cytologically confirmed SCLC with combined histologies.
  • Have received any of the following therapies or drugs within the noted time intervals prior to study treatment:

    • Within 2 weeks: small molecule agents with half-life of \<7 days; radiation outside the thoracic cavity including whole brain radiation. Of note, other local radiation for brain lesions (not whole brain) is allowed; local radiation for bone lesions is allowed. Palliative bone radiation or brain stereotactic radiosurgery would not require a , but participants should recover from radiotherapy-related toxicity.
    • Within 4 weeks: radiation involving the thoracic cavity; small molecule targeted agents with half-life of ≥7 days; monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or T-cell or other cell-based therapies.
    • Have received prior treatment with anti-vascular endothelial growth factor (VEGF) monoclonal antibody, or programmed death (ligand)-1 (PD[L]-1)/VEGF bispecific antibody.
    • Have received systemic (at a dosage greater than 10 mg/day of prednisone or an equivalent dose of other corticosteroids) within 7 days prior to the initiation of study treatment. Note: local, intranasal, intraocular, intra-articular or inhaled corticosteroids, short-term use (≤7 days) of corticosteroids for prophylaxis (e.g., prevention of contrast agent allergy) or treatment of non- conditions (e.g., delayed reactions caused by exposure to allergens) are allowed.
  • Have the following central nervous system :

    • Participants with untreated that are symptomatic or large (e.g., greater than 2 cm).
    • Participants with treated central nervous system (CNS) metastases who are not neurologically stable or on steroids (at a dosage greater than 10 mg/Day of prednisone or an equivalent dose of other corticosteroid) within 7 days before initiating study treatment of this study.
    • Participants with known .
  • Have uncontrolled hypertension or poorly controlled diabetes prior to study treatment.
  • Have a serious or non-healing wound, or (incompletely healed) bone fracture. This includes history of abdominal fistula, tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess for which an interval of 6 months must pass before study entry. In addition, the participant must have undergone correction (or spontaneous healing) of the perforation/fistula and/or the underlying process causing the fistula/perforation.
  • Have a significant risk of hemorrhage (per investigator clinical judgment) as defined in the protocol.
  • Have superior vena cava syndrome or symptoms of spinal cord compression that requires urgent medical intervention.

NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
621 participants (estimated)

Study arms

  • Active comparator
    Stage 1 Control Arm - Atezolizumab + Etoposide + Carboplatin

    Drug: Atezolizumab · Drug: Etoposide · Drug: Carboplatin (or cisplatin if carboplatin is not tolerated)

  • Experimental
    Stage 1 Treatment Arm 1 - Pumitamig Dose 1 + Etoposide + Carboplatin

    Drug: Pumitamig · Drug: Etoposide · Drug: Carboplatin (or cisplatin if carboplatin is not tolerated)

  • Experimental
    Stage 1 Treatment Arm 2 - Pumitamig Dose 2 + Etoposide + Carboplatin

    Drug: Pumitamig · Drug: Etoposide · Drug: Carboplatin (or cisplatin if carboplatin is not tolerated)

  • Active comparator
    Stage 2 Control Arm - Atezolizumab + Etoposide + Carboplatin

    Drug: Atezolizumab · Drug: Etoposide · Drug: Carboplatin (or cisplatin if carboplatin is not tolerated)

  • Experimental
    Stage 2 Treatment Arm - Pumitamig Dose 3 + Etoposide + Carboplatin

    Drug: Pumitamig · Drug: Etoposide · Drug: Carboplatin (or cisplatin if carboplatin is not tolerated)

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    OS defined as the time from randomization to death from any cause.

    Time frame: Up to approximately 46 months

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS defined as the time from randomization to first objective tumor progression (progressive disease per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\]), or death from any cause, whichever occurs first.

    Time frame: Up to approximately 46 months

  2. Objective response rate (ORR)

    ORR defined as the proportion of participants in whom a complete response (CR) or partial response (PR) (based on investigator's assessment per RECIST v1.1) is observed as best overall response with confirmation.

    Time frame: Up to approximately 46 months

  3. Duration of response (DOR)

    DOR defined as the time from onset of objective response (confirmed CR or PR based on investigator's assessment per RECIST v1.1) to first occurrence of objective tumor progression (progressive disease per RECIST v1.1) or death from any cause, whichever occurs first.

    Time frame: Up to approximately 46 months

  4. PFS rate based on investigator's assessment

    Time frame: At 6, 12, and 18 months

  5. OS rate

    Time frame: At 6, 12, 18, and 24 months

  6. Occurrence of treatment-emergent adverse events (TEAEs) including Grade ≥3, serious, and fatal TEAEs by relationship

    TEAEs graded according to (US) National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0

    Time frame: From the first dose of study treatment to the 90-Day Follow-up Visit

  7. Occurrence of dose delay, infusion interruption and discontinuation of study treatment due to TEAEs (including related TEAEs)

    Time frame: From first to last dose of study treatment, i.e., up to 2 years

  8. Change from baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Core 30 questionnaire (QLQ-C30) Global Health status/Quality-of-Life score (Items 29 and 30)

    Global health status/QoL scale ranges in score from 0 to 100 with a high scale score representing a higher response level (e.g., high score for global health status/QoL is high QoL: high score for symptom scale/item is high symptomatology or problems).

    Time frame: Up to approximately 46 months

  9. Change from baseline in EORTC QLQ-C30 physical functioning

    Physical functioning scale ranges in score from 0 to 100 with a high scale score representing a higher response level (e.g., high score for functional scale is high/healthy level of functioning).

    Time frame: Up to approximately 46 months

  10. Change from baseline in coughing scale of the EORTC Quality-of-Life-Lung cancer 29 questionnaire (QLQ-LC29)

    Multi-item coughing scale ranges in score from 0 to 100 with a high score representing a high level of symptomatology or problems.

    Time frame: Up to approximately 46 months

  11. Change from baseline in shortness of breath scale of the EORTC QLQ-LC29

    Multi-item shortness of breath scale ranges in score from 0 to 100 with a high score representing a high level of symptomatology or problems.

    Time frame: Up to approximately 46 months

  12. Change from baseline in coughed up blood item of the EORTC QLQ-LC29

    Single item coughing up blood ranges in score from 0 to 100 with a high score representing a high level of symptomatology or problems.

    Time frame: Up to approximately 46 months

  13. Change from baseline in Functional Assessment of Cancer Therapy-General overall bother item (FACT-GP5).

    The FACT-G - Item GP5 (Version 4) is a single-item summary measure of the overall impact of treatment toxicity, based upon its association with the number and degree of AEs in clinical studies, rated on a 5-point Likert scale ("not at all" to "very much") with a recall period of past 7 days. A high score represents high level of problems.

    Time frame: Up to approximately 46 months

07

Study locations

188 of 225 sites recruiting

Showing the first 100 of 225 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Apr 2029, 50 months after the start.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 50 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Dec 2028 → Apr 2029 and completion Mar 2029 → Jul 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2024
First posted
Dec 2, 2024
StartActual
Feb 3, 2025
Primary completionEst.
Apr 2029was Dec 2028
CompletionEst.
Jul 2029was Mar 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2028→Apr 2029
Oct 14, 2026
Study completion
Mar 2029→Jul 2029
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Dec 2028→Apr 2029
    Study completion Mar 2029→Jul 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06712355
Lead sponsor
BioNTech SE
Responsible party
Sponsor
First posted
Dec 2, 2024
Start date
Feb 3, 2025
Primary completion
Apr 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

BioNTech clinical trials patient information
Contact
patients@biontech.de
+49 6131 9084 ext. 0
BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pumitamig

Start the discussion